Atlas Funds Losses?

Soreide Law Group is investigating potential investor claims involving sales practice violations by securities brokers and financial advisors relating to Atlas Funds private placement offerings. These Atlas Funds offerings were marketed as a way for investors to obtain indirect exposure to specific pre-IPO companies through a layered fund structure. FINRA’s Department of Enforcement filed a disciplinary Complaint describing alleged Regulation Best Interest (Reg BI) failures, misleading disclosures, and conflicts of interest tied to the recommendations and sales of these Offerings. The sections below summarize the key allegations investors should know.

Overview

According to the FINRA Complaint, the Atlas Funds consisted of three unregistered private investment funds—Atlas Fund III LLC, Atlas Fund IV LLC, and Atlas Fund V LLC—organized as Delaware limited liability companies and managed by Atlas Fund Management LLC. The Offerings were sold as 16 separate series offerings, and investors (who were Spartan clients) purchased membership interests in a particular series intended to provide indirect exposure to one pre-IPO company selected for that series. Investor proceeds were then used to purchase membership interests in SP Venture Fund 8 LLC (also described as the “StraightPath Fund”), a private fund managed by StraightPath Venture Partners LLC, which purportedly held pre-IPO shares.

Concerns About The Atlas Funds

FINRA alleges that between March 2021 and October 2021, Spartan made 346 recommendations totaling more than $24 million to 191 clients, with most recommendations made to retail clients, and generated over $2.4 million in placement fees. FINRA contends Spartan lacked a reasonable basis for these recommendations because it failed to conduct reasonable due diligence, including verifying that StraightPath Fund actually possessed or had access to the pre-IPO shares tied to the series offerings.

The Complaint alleges that documentation to confirm StraightPath’s holdings was not requested until March 31, 2021—after three offerings were already sold and funded—and that follow-ups were unanswered for months while additional offerings continued to be sold. FINRA also alleges that materials disseminated to investors contained misstatements about markups and transaction mechanics, including the use of an affiliated entity, Iapetus LLC, which was described as an intermediary in supplements even though FINRA alleges Atlas purchased interests directly and then charged investors markups. FINRA states total markups charged to clients were approximately $3.25 million, ranging from about 12.75% to 36.4%, and alleges these markups benefited the owner/control person. The Complaint further alleges conflicts were not fully and fairly disclosed in writing, including ownership/control relationships and roles of key personnel, and that written supervisory procedures for private placements and conflict management were inadequate.

Potential Sales Practice Violations

Based on the issues described in the FINRA Complaint, investors who suffered losses may question whether they received recommendations that were unsuitable or not in their best interest, whether material facts about pricing, markups, fees, and conflicts were misrepresented or omitted, and whether adequate due diligence and supervision occurred before the product was offered. Common sales practice violations in similar matters include unsuitable recommendations, failure to disclose conflicts and compensation incentives, misrepresentations in offering documents, and failure to supervise representatives and private placement due diligence. Investors who experienced these issues may have rights to pursue recovery through FINRA arbitration or litigation, depending on the facts of their situation.

Did You Sustain Losses By Investing In The Atlas Funds?

Did you suffer any investment-related losses because of investing in Atlas Funds private placement offerings because of your financial advisor or securities broker? Contact Soreide Law Group online  or at (888) 760-6552 and consult with a securities attorney regarding a potential recovery of your investment losses. Soreide Law Group has recovered losses for investors throughout the US. The firm works on a contingency fee basis and advances all costs.